Distinct changes in brain and peripheral oxygen levels induced by synthetic opioids of the nitazene family

Nitazenes are a category of synthetic opioids, some of which have high analgesic potential but also high toxicity, which has historically prevented their development as therapeutic drugs. Like fentanyl, nitazenes induce respiratory depression, a primary factor in their toxicity. Recently, a nitazene derivative called N-desethyl-fluornitrazene (DFNZ) was shown to have high analgesic properties with weak hypoxic effects. To better characterize the hypoxic effects of DFNZ relative to its parent, fluornitrazene (FNZ) and the prototypical nitazene etonitazene, we used amperometric oxygen sensors in freely moving rats to examine oxygen dynamics in the nucleus accumbens (NAc) and the subcutaneous space, using fentanyl as a comparison. All drugs induced similar patterns of subcutaneous hypoxia, with rapid dose-dependent oxygen decreases. In the NAc, all opioids, except DFNZ, at low iv doses (1-5 μg/kg) induced moderate but significant brain oxygen increases. At higher doses (>10 μg/kg), oxygen levels for all opioids, except DFNZ, showed a biphasic response; robust hypoxia followed by a weaker rebound-like hyperoxia. Etonitazene at 30 μg/kg had the largest and most prolonged brain hypoxia compared to the other drugs, without the rebound-like hyperoxia. These findings indicate that etonitazene and FNZ mimic the effects of fentanyl, inducing dose-dependent brain and peripheral hypoxia. In contrast, DFNZ induces very weak hypoxia seen minimally at very high iv doses (300-1000 μg/kg). Our findings substantiate the low hypoxic potency of DFNZ and indicate that not all nitazenes are characterized by high potential for toxicity. As such, the development of nitazenes as analgesics should not be categorically dismissed.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.766190
Primary Topic
Forensic Toxicology and Drug Analysis
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Distinct changes in brain and peripheral oxygen levels induced by synthetic opioids of the nitazene family

Eugene A. Kiyatkin, Agnieszka Sulima, Juan L. Gomez, Kenner C. Rice et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Forensic Toxicology and Drug Analysis
preprint

Distinct changes in brain and peripheral oxygen levels induced by synthetic opioids of the nitazene family

Eugene A. Kiyatkin, Agnieszka Sulima, Juan L. Gomez, Kenner C. Rice, Michael Michaelides, Ali Arce, Nicholas Nguyen
preprint en

Abstract

Nitazenes are a category of synthetic opioids, some of which have high analgesic potential but also high toxicity, which has historically prevented their development as therapeutic drugs. Like fentanyl, nitazenes induce respiratory depression, a primary factor in their toxicity. Recently, a nitazene derivative called N-desethyl-fluornitrazene (DFNZ) was shown to have high analgesic properties with weak hypoxic effects. To better characterize the hypoxic effects of DFNZ relative to its parent, fluornitrazene (FNZ) and the prototypical nitazene etonitazene, we used amperometric oxygen sensors in freely moving rats to examine oxygen dynamics in the nucleus accumbens (NAc) and the subcutaneous space, using fentanyl as a comparison. All drugs induced similar patterns of subcutaneous hypoxia, with rapid dose-dependent oxygen decreases. In the NAc, all opioids, except DFNZ, at low iv doses (1-5 μg/kg) induced moderate but significant brain oxygen increases. At higher doses (>10 μg/kg), oxygen levels for all opioids, except DFNZ, showed a biphasic response; robust hypoxia followed by a weaker rebound-like hyperoxia. Etonitazene at 30 μg/kg had the largest and most prolonged brain hypoxia compared to the other drugs, without the rebound-like hyperoxia. These findings indicate that etonitazene and FNZ mimic the effects of fentanyl, inducing dose-dependent brain and peripheral hypoxia. In contrast, DFNZ induces very weak hypoxia seen minimally at very high iv doses (300-1000 μg/kg). Our findings substantiate the low hypoxic potency of DFNZ and indicate that not all nitazenes are characterized by high potential for toxicity. As such, the development of nitazenes as analgesics should not be categorically dismissed.

bioRxiv (Cold Spring Harbor Laboratory)
National Institutes of Health (US), National Institute on Drug Abuse (US), National Research Council of Thailand (TH)
U.S. Department of Health and Human Services, National Institutes of Health
Good health and well-being
Forensic Toxicology and Drug Analysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon